Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599137 | 0.87 | CCR5 (0.31) | — | |
| SCHEMBL5599195 | 0.69 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2711031 | 0.67 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2725528 | 0.67 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12086030 | 0.67 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12086061 | 0.67 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12086089 | 0.66 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2710186 | 0.66 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2726055 | 0.65 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2711599 | 0.64 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158419-A1 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158419-A1 | Method for producing biaryl compound | B2M, BMI1, CYP2W1 | CYP1A2 18/4885CYP3A4 101/4885CYP2C9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.